Vivia Biotech, Preclinical and Translational CRO to enable Cancer Drug and Biomarker Discovery & Development

Our assays cover many aspects of primary cell biology with a special emphasis on preserving native microenvironment in hematological ex vivo (blood and marrow) systems. Follow the links for more information.

We count on high qualified expertise from our dedicated staff, external consultants and collaborators.

We can also adapt to your specific needs, please contact us to discuss your project requirements.

Cytotoxic Drugs Assays

Antiproliferative Drugs Testing

Complement-Dependent Cytotoxicity Assay (CDC)

Antibody-Dependent Cellular Cytotoxicity Assay (ADCC)

Bispecific Antibodies Testing

Immune Oncology Drugs Testing

Hematotoxicity Assay

Differentiation Assay

MRD+ Cells Assay

Targeted Drugs Testing

CART Cells Assays

Custom Assays

Cytotoxic Compounds Testing

Bispecific Antibodies Testing

Immune Oncology Drugs Testing

TILs Expansion

Custom Assays

Combined Functional and Molecular Studies

NGS methods

Compound Profiling by Flow Cytometry

Data Analysis for Molecular Biology Assays

Advanced Analysis and Visualization through TIBCO Spotfire

Vivia performs feasibility studies to accurately foresee the collection timelines, and puts its own experience, together with our collaborators’s clinical expertise at our customers’ disposal to help you improve your research lines and results.

Vivia’s standard procedures guarantees the suitability and highest quality of samples with a variety of features for our customer’s research. All samples and clinical data from patients who meet the predefined inclusion and exclusion criteria are collected in accordance with GCP guidelines and applicable laws, within the approval framework of the competent Ethics Committee and after patient’s declared consent.

Vivia offers to its partners proprietary Native Environment Assays in patient’s whole bone marrow, assessing the drug activity in the native tumor microenvironment:

Assays include state of the art immune-oncology (IO drugs, CAR-T), and microenvironment assays (BCR inhibitors)
Key deliveries of PharmaFlow PM for your drug development:
Direct impact in ROI over 90% CR in clinical trials as CDx
Identification of early molecular biomarkers of efficacy/resistance
Better understanding of MOA & interpatient variability of response
Best combos to increase market share & overcome resistance in clinical trials
Market positioning vs. SOC and competitive drugs